目次

1. Research Methodology

2. Global Lymphoma Antibody Therapeutics Market
2.1 Current Market Scenario
2.2 Regional Market Analysis
2.3 Future Market Opportunity

3. Lymphoma Antibody Drug Conjugates - Availability, Dosage, Patent, and Price Analysis
3.1 Brentuximab Vedotin (Adcetris)
3.2 Polatuzumab vedotin (Polivy)
3.3 Loncastuximab Tesirine (Zynlonta)

4. Lymphoma Monoclonal Antibodies - Availability, Patent, Price and Dosage Analysis
4.1 Nivolumab (Opdivo)
4.2 Tafasitamab (Monjuvi/Minjuvi)
4.3 Rituximab (Mabthera/Rituxan)
4.4 Rituximab Biosimilar (Truxima)
4.5 Rituximab Biosimilar (Riabni)
4.6 Rituximab Biosimilar (Ruxience)
4.7 Rituximab/Hyaluronidase (Rituxan Hycela)
4.8 Obinutuzumab (Gazyva)
4.9 Pembrolizumab (Keytruda )
4.10 Sintilimab (Tyvyt)
4.11 Camrelizumab (AiRuiKa)
4.12 Tislelizumab (Baize’an)
4.13 Zimberelimab
4.14 Penpulimab

5. Lymphoma Antibody Drug Conjugates - Global and Regional Sales Analysis
5.1 Adcetris
5.2 Polivy
5.3 Zynlonta

6. Lymphoma Monoclonal Antibodies - Global and Regional Sales Analysis
6.1 Opdivo
6.2 Monjuvi
6.3 Rituxan
6.4 Gazvya
6.5 Keytruda

7. Global Lymphoma Antibodies Clinical Trials Overview
7.1 By Company
7.2 By Country
7.3 By Phase
7.4 By Patient Segment

8. Global Lymphoma Antibodies Clinical Trials By Company, Indication and Phase
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-II/III
8.7 Phase-III
8.8 Preregistration
8.9 Registered

9. Marketed Lymphoma Antibodies Clinical Insight by Company, Country and Indication

10. Competitive Landscape
10.1 AbbVie
10.2 ADC Therapeutics
10.3 BeiGene
10.4 Bristol Myers Squibb
10.5 GlaxoSmithKline
10.6 Innovent
10.7 Merck
10.8 Morphosys
10.9 Ono Pharmaceutical
10.10 Pfizer
10.11 Roche
10.12 Seagen
10.13 Takeda Pharmaceuticals

List of Figures & Tables
Figure 2-1: Global - Hodgkin Lymphoma Incidences and Deaths (Million), 2020 and 2030
Figure 2-2: Global - Non- Hodgkin Lymphoma Incidences and Deaths (Million), 2020 and 2030
Figure 2-3: Global - Lymphoma Antibodies Therapeutics Market Size (US$ Billion), 2018 - 2021
Figure 2-4: Global - Lymphoma Antibodies Therapeutics Market Size by Product Value (%), 2021
Figure 2-5: Global - Lymphoma Antibodies Therapeutics Market Size by Region (US$ Million), 2021
Figure 2-6: Global - Lymphoma Antibodies Therapeutics Market Size by Region (%), 2021
Figure 2-7: Global - Lymphoma Antibodies Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 3-1: US - Adcetris Oprhan Drug Designation Approval Year by Indication
Figure 3-2: US - Adcetris FDA Approval Year by Indication
Figure 3-3: Adcetris - Approval Year by Region
Figure 3-4: Japan - Adcetris FDA Approval Year by Indication
Figure 3-5: Adcetris - Patent Expiration by Region
Figure 3-6: UK - Cost of Supply of Adcetris 50mg Intravenous Powder (GBP/US$), May’2022
Figure 3-7: Adcetris - Cost of Supply of Vial for Injection by Region (US$), May’2022
Figure 3-8: Adcetris - Duration of Single Treatment Cycle and Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (Weeks)
Figure 3-9: Adcetris - Maximum Cost of Single Treatment Cycle and Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (US$), May’2022
Figure 3-10: Adcetris - Duration of Single Treatment Cycle and Full Treatment of Classical Hodgkin Lymphoma (Weeks)
Figure 3-11: Adcetris - Maximum Cost of Single Treatment Cycle and Full Treatment of Classical Hodgkin Lymphoma (US$), May’2022
Figure 3-12: Adcetris - Maximum Cost of Single Treatment Cycle and Full Treatment of Previously Untreated Systemic ALCL or Other CD30 T-Cell Lymphomas (US$), January'2022
Figure 3-13: Adcetris - Duration of Single Treatment Cycle and Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (Weeks)
Figure 3-14: Adcetris - Maximum Cost of Single Treatment Cycle and Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (US$), January'2022
Figure 3-15: Polivy - Orphan Drug Designation Approval Year by Region
Figure 3-16: US - Polivy Orphan Drug Designation Approval and Exclusivity Year
Figure 3-17: Polivy - Approval Year by Region
Figure 3-18: US - Price for Single Unit of Polivy 30mg and 140mg Intravenous Powder for Injection (US$), May’2022
Figure 3-19: UK - Price for Single Unit of Polivy 30mg and 140mg Intravenous Powder for Injection (GBP/US$), May’2022
Figure 3-20: Polivy - Duration of Single Treatment Cycle and Full Treatment (Weeks)
Figure 3-21: Polivy - Cost of Single Dose, Single Treatment Cycle and Full Treatment of DLBCL (US$), May’2022
Figure 3-22: US - Zynlonta FDA Orphan Drug Designation Approval and Patent Exclusivity Year
Figure 3-23: US - Zynlonta Orphan Drug Designation and FDA Approval Year
Figure 3-24: Zynlonta - Orphan Drug Designation by Region
Figure 3-25: Zynlonta - Average Cost of Single Treatment Cycle and Annual Treatment Cost (US$), May’2022
Figure 3-26: Zynlonta - Recommended Dose for Initial and Subsequent Cycles (mg/kg)
Figure 4-1: Opdivo - Approval Year by Region
Figure 4-2: Opdivo - FDA Approval by Indication
Figure 4-3: Opdivo - Patent Expiration Year by Region
Figure 4-4: US - Price for 4ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), May’2022
Figure 4-5: US - Price for 10 ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), May’2022
Figure 4-6: US - Price for 12 ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), May’2022
Figure 4-7: US - Price for 24 ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), May’2022
Figure 4-8: UK - Price for 4 ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (GBP/US$), May’2022
Figure 4-9: UK - Price for 10ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (GBP/US$), May’2022
Figure 4-10: UK - Price for 24ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (GBP/US$), May’2022
Figure 4-11: Opdivo Monotherapy Therapy - Single Treatment Cycle and Full Treatment Average Cost (US$), May’2022
Figure 4-12: Tafasitamab - Approval Year by Region
Figure 4-13: Monjuvi - Number of Dose per Treatment Cycle by Phase
Figure 4-14: Monjuvi - Duration of Single Treatment Cycle and Full Treatment (Weeks)
Figure 4-15: Monjuvi - Cost of Single Dose, Single Treatment Cycle and Full Treatment (US$), May’2022
Figure 4-16: Rituxan - FDA Approval Year by Indication
Figure 4-17: MabThera - Approval Year by Region
Figure 4-18: US- Price for a Supply of 10 ml and Price Per ml of Rituxan Solution for Injection (US$), May’2022
Figure 4-19: US - Price for a Supply of 50 ml and Price Per ml of Rituxan Solution for Injection (US$), May’2022
Figure 4-20: US - Price for a Supply of 100 ml and Price Per ml of Solution Rituxan for Injection (US$), May’2022
Figure 4-21: UK - Price for a Supply of 10 ml and Price Per ml of Rituxan Solution for Injection (GBP/US$), May’2022
Figure 4-22: UK - Price for a Supply of 50 ml and Price Per ml of Rituxan Solution for Injection (GBP/US$), May’2022
Figure 4-23: Rituxan - Average Minimum and Maximum Cost for Refractory CD20+ B-Cell NHL Management (US$), May’2022
Figure 4-24: Rituxan - Average Cost for Single Dose and Cost of Full Maintenance Phase for CLL (US$), May’2022
Figure 4-25: Truxima - Price for a Supply of 10 ml and Price Per ml of Solution for Injection (US$), May’2022
Figure 4-26: Truxima - Price for a Supply of 50 ml and Price Per ml of Solution for Injection (US$), May’2022
Figure 4-27: UK - Cost of 50ml Truxima 500mg/50ml Solution and Per Unit Cost of Solution (GBP/US$), May’2022
Figure 4-28: UK - Cost of 2 Vials of Truxima 100mg/10ml Solution and Per Unit Cost of Vial (GBP/US$), May’2022
Figure 4-29: Truxima - Average Minimum and Maximum Cost for Refractory CD20+ B-Cell NHL Management (US$), May’2022
Figure 4-30: Truxima - Average Cost for Single Dose and Cost of Full Maintenance Phase for CLL (US$), May’2022
Figure 4-31: Riabni - Cost of Supply of 10ml and Per Unit Price of 10mg/ml Intravenous Solution (US$), May’2022
Figure 4-32: Riabni - Cost of Supply of 50ml and Per Unit Price of 10mg/ml Intravenous Solution (US$), May’2022
Figure 4-33: Riabni - Cost of 8 Cycles, 4 Cycles and Single Cycle for Management of NHL (US$), February’2022
Figure 4-34: Ruxience - Approval Year by Region
Figure 4-35: US - Cost of Supply of 10ml and Per Unit Price of Ruxience 10mg/ml Intravenous Solution (US$), May2022
Figure 4-36: US - Cost of Supply of 50ml and Per Unit Price of Ruxience 10mg/ml Intravenous Solution (US$), May2022
Figure 4-37: UK - Cost of 50ml Ruxience 500mg/50ml Solution and Per Unit Cost of Solution (GBP/US$), May’2022
Figure 4-38: UK - Cost of 10ml Ruxience 100mg/10ml Solution and Per Unit Cost of Solution (GBP/US$), May’2022
Figure 4-39: Ruxience - Cost of 8 Cycles, 4 Cycles and Single Cycle for Management of NHL (US$), February’2022
Figure 4-40: Rituxan Hycela - Price for 11.7 ml Supply and Price Per ml of 23,400 units-1,400mg/11.7 ml Subcutaneous Solution (US$), May’2022
Figure 4-41: Rituxan Hycela - Price for 13.4 ml Supply and Price Per ml of 26,800 units-1,600 mg/13.4ml Subcutaneous Solution (US$), May’2022
Figure 4-42: Rituxan Hycela -Minimum and Maximum Duration of Follicular lymphoma Treatment (Weeks)
Figure 4-43: Rituxan Hycela - Average Minimum and Maximum Cost of Follicular lymphoma (US$), May’2022
Figure 4-44: Rituxan Hycela - Duration of Single Treatment Cycle and Full Treatment of Previously Untreated Follicular lymphoma (weeks)
Figure 4-45: Rituxan Hycela - Average Minimum and Maximum Cost of Previously Untreated Follicular lymphoma (US$), May’2022
Figure 4-46: Rituxan Hycela - Average Minimum and Maximum Cost of Diffuse Large B-Cell Lymphoma (US$), May’2022
Figure 4-47: Rituxan Hycela - Duration of CLL Treatment (Weeks)
Figure 4-48: Rituxan Hycela - Cost of Single Treatment Cycle and Full Treatment of CLL (US$), May’2022
Figure 4-49: Gazyva - Approval Year by Cancer Type
Figure 4-50: Gazyva - Price for 40ml Supply and Price Per ml of Intravenous Solution (US$), May’2022
Figure 4-51: Gazyva - Recommended Dosing Schedule for Initial Treatment Cycle of Lymphoma (mg)
Figure 4-52: Gazyva - Minimum and Maximum Duration for Follicular Lymphoma Treatment (Week)
Figure 4-53: Gazyva - Cost of Initial and Subsequent Treatment Cycle of Lymphoma (US$), May’2022
Figure 4-54: Gazyva - Duration of Single Treatment Cycle and Full Treatment Using Monotherapy (Months), February’2022
Figure 4-55: Keytruda - Approval Year by Region
Figure 4-56: Keytruda - FDA Approval Year by Indication
Figure 4-57: Keytruda - Patent Expiration Year by Region
Figure 4-58: US - Price for 4ml, 8ml Supply and Price Per ml of Keytruda Intravenous Injection (US$), May’2022
Figure 4-59: UK - Price for 4ml and Price Per ml of Keytruda 100mg Intravenous Injection (GBP/US$), May’2022
Figure 4-60: Keytruda - Duration of Single Treatment Cycle and Full Treatment of Melanoma and Other Cancers (Weeks), May’2022
Figure 4-61: Tyvyt - NMPA Approval by Indication
Figure 4-62: China- Price for Vial of AiRuiKa (Yuan/US$), May’2022
Figure 4-63: Tislelizumab - NMPA Approval by Indication
Figure 4-64: China- Price for Vial of Penpulimab (Yuan/US$), May’2022
Figure 5-1: Global - Adcetris Quarter 1 Sales (US$ Million), 2021 and 2022
Figure 5-2: Global - Adcetris Annual Sales (US$ Million), 2018 - 2021
Figure 5-3: Global - Adcetris Quarterly Sales (US$ Million), 2021
Figure 5-4: Global - Adcetris Quarterly Sales (US$ Million), 2020
Figure 5-5: Polivy - Quarter -1 Value by Region (US$/CHF Million), 2022
Figure 5-6: Global - Polivy Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 5-7: Global - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 5-8: US - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 5-9: Europe - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 5-10: Japan - Polivy Quarterly Sales Value (US$/CHF Million), Q2-Q4’2021
Figure 5-11: ROW - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 5-12: Polivy - Annual Sales Value by Region (US$/CHF Million), 2021
Figure 5-13: Polivy - Quarterly Sales Value by Region (%), 2021
Figure 5-14: Global - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 5-15: US - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 5-16: Europe - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 5-17: Polivy - Annual Sales Value by Region (US$/CHF Million), 2020
Figure 5-18: Polivy - Annual Sales Value by Region (%), 2020
Figure 5-19: Polivy - Quarterly Sales Value (US$/CHF Million), Q2-Q4'2019
Figure 5-20: Global - Zynlonta Quarterly Sales (US$ Million), Q2 and Q3'2021
Figure 6-1: Global - Opdivo Quarter 1 Sales Value by Region (US$ Million), 2022
Figure 6-2: Global - Opdivo Quarter 1 Sales Value by Region (%), 2022
Figure 6-3: Global - Opdivo Annual Sales Value (US$ Million), 2018-2021
Figure 6-4: US - Opdivo Annual Sales Value (US$ Million), 2018-2021
Figure 6-5: Global - Opdivo Annual Sales Value by Region (US$ Million), 2021
Figure 6-6: Global - Opdivo Annual Sales Value by Region (%), 2021
Figure 6-7: Global - Opdivo Quarterly Sales Value (US$ Million), 2021
Figure 6-8: US - Opdivo Quarterly Sales Value (US$ Million), 2021
Figure 6-9: Global - Opdivo Quarterly Sales Value (US$ Million), 2020
Figure 6-10: US - Opdivo Quarterly Sales Value (US$ Million), 2020
Figure 6-11: US - Monjuvi Annual Sales Value (US$ Million), 2020 and 2021
Figure 6-12: US - Monjuvi Quarterly Sales Value (US$ Million), 2021
Figure 6-13: US - Monjuvi Quarterly Sales Value (US$ Million), Q3 and Q4, 2020
Figure 6-14: Polivy - Quarter -1 Value by Region (US$/CHF Million), 2022
Figure 6-15: Global - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 6-16: US - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 6-17: Europe - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 6-18: Japan - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 6-19: ROW - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 6-20: Rituxan - Annual Sales Value by Region (US$/CHF Million), 2021
Figure 6-21: Rituxan - Annual Sales Value by Region (%), 2021
Figure 6-22: Global - Rituximab Quarterly Sales Value (US$ Billion), 2021
Figure 6-23: Global - Rituxan Quarterly Sales Value (US$ Million), 2020
Figure 6-24: Polivy - Quarter -1 Value by Region (US$/CHF Million), 2022
Figure 6-25: US - Gazyva Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 6-26: US - Gazyva Quarterly Sales Value (US$ Billion), 2021
Figure 6-27: US - Gazyva Quarterly Sales Value (US$/CHF Million), 2020
Figure 6-28: Global - Adcetris Quarter 1 Sales (US$ Million), 2021 and 2022
Figure 6-29: Global - Keytruda Annual Sales Value (US$ Billion), 2018 - 2021
Figure 6-30: Global - Keytruda Quarterly Sales Value (US$ Billion), 2021
Figure 6-31: Global - Keytruda Quarterly Sales Value (US$ Billion), 2020
Figure 7-1: Global Lymphoma Antibodies in Clinical Trials by Company, 2022 till 2028
Figure 7-2: Global Lymphoma Antibodies in Clinical Trials by Company, 2022 till 2028
Figure 7-3: Global Lymphoma Antibodies in Clinical Trials by Phase, 2022 till 2028
Figure 7-4: Global Lymphoma Antibodies in Clinical Trials by Patient Segment, 2022 till 2028